Signal Transduction Inhibitors in the Treatment of Breast Cancer

Author(s): Rita Nahta, Gabriel N. Hortobagyi, Francisco J. Esteva.

Journal Name: Current Medicinal Chemistry - Anti-Cancer Agents

Volume 3 , Issue 3 , 2003

Become EABM
Become Reviewer

Abstract:

Signal transduction pathways are frequently altered in human breast cancer and are the targets of several novel therapies currently in clinical trials. Therapeutic strategies include extracellular blockade of tyrosine kinase receptors with the monoclonal antibodies C225 and trastuzumab. Competitive inhibitors of adenosine triphosphate binding sites on tyrosine and serine / threonine kinases are also being evaluated in phase I / II trials, these include ZD1839, OSI-774 and CI- 1033. Flavopiridol and UCN-01 are nonspecific cell cycle kinase antagonists with preliminary evidence of breast cancer cell growth inhibition. Several inhibitors of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling are also in various stages of preclinical or clinical development. Additionally, inhibitors of farnesyl transferase have demonstrated activity in breast cancer cells irrespective of ras status. Current evidence suggests that targeting of signaling molecules is a promising new approach to treatment of breast cancer.

Keywords: breast neoplasm, biological therapy, egfr, her-2, monoclonal antibodies, tyrosine kinase inhibitors, farnesyl transferase inhibitors

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 3
ISSUE: 3
Year: 2003
Page: [201 - 216]
Pages: 16
DOI: 10.2174/1568011033482468
Price: $58